{
    "clinical_study": {
        "@rank": "143134", 
        "brief_summary": {
            "textblock": "This is a study of a melanoma tumor antigen peptide vaccine.  Peptides representing HLA-A201\n      restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be\n      administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with\n      melanoma.  The study is designed to evaluate the potential therapeutic role, immunologic\n      effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously.\n\n      Immune reactivity to the peptide epitope will be monitored in all patients by analysis of\n      melanoma-specific T cell precursors prior to and after immunization."
        }, 
        "brief_title": "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase", 
        "completion_date": "September 2000", 
        "condition": [
            "Melanoma", 
            "Neoplasm Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a study of a melanoma tumor antigen peptide vaccine.  Peptides representing HLA-A201\n      restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be\n      administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with\n      melanoma.  The study is designed to evaluate the potential therapeutic role, immunologic\n      effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously.\n\n      Immune reactivity to the peptide epitope will be monitored in all patients by analysis of\n      melanoma-specific T cell precursors prior to and after immunization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Any patient 16 years of age or older with measurable metastatic melanoma who has failed\n        standard treatment and has an expected survival of greater than three months.\n\n        Must be HLA-A0201.\n\n        Serum creatinine of 2.0 mg/dl or less.\n\n        Bilirubin 1.6 mg/dl or less.\n\n        WBC 3000/mm(3) or greater.\n\n        Platelet count 90,000 mm(3) or greater.\n\n        Serum AST/ALT less then two times normal.\n\n        ECOG performance status of 0 or 1.\n\n        Patients of both genders must be willing to practice effective birth control during the\n        trial.\n\n        Must not be undergoing or have undergone in the past 3 weeks any other form of therapy\n        except surgery for their cancer.\n\n        Must not have active systemic infections, coagulation disorders, or other major medical\n        illnesses of the cardiovascular or respiratory systems or any known immunodeficiency\n        disease.\n\n        Must not require steroid therapy.\n\n        Must not be pregnant.\n\n        Must not be positive for hepatitis B(s)AG or HIV antibody.\n\n        Must not have had a known allergic reaction to Incomplete Freund's Adjuvant (IFA)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "114", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001685", 
            "org_study_id": "980023", 
            "secondary_id": "98-C-0023"
        }, 
        "intervention": {
            "intervention_name": "Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Cancer", 
            "IL-12", 
            "IL-2", 
            "Immunotherapy", 
            "Vaccine"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "9136454", 
                "citation": "Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997 Apr;18(4):175-82. Review. No abstract available."
            }, 
            {
                "PMID": "8931607", 
                "citation": "Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 1996 Nov 20;88(22):1635-44. Review."
            }, 
            {
                "PMID": "9500606", 
                "citation": "Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001685"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 1997", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1999"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}